# Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

> **NCT05256641** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Lymphoma
- Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT05256641
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256641, "Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05256641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*